Shares of ResMed Inc. (NYSE:RMD) have been assigned an average recommendation of “Hold” from the thirteen research firms that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $72.25.
Several research firms have weighed in on RMD. Zacks Investment Research raised ResMed from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research report on Friday, February 2nd. Needham & Company LLC raised ResMed from an “underperform” rating to a “hold” rating in a report on Tuesday, January 23rd. Northland Securities raised ResMed from an “under perform” rating to a “market perform” rating in a report on Tuesday, January 23rd. BMO Capital Markets boosted their target price on ResMed to $90.00 and gave the stock a “market perform” rating in a report on Tuesday, January 23rd. Finally, Barclays boosted their target price on ResMed from $68.00 to $70.00 and gave the stock an “underweight” rating in a report on Friday, October 27th.
In other news, Director Ronald R. Taylor sold 4,885 shares of the company’s stock in a transaction on Wednesday, January 24th. The stock was sold at an average price of $99.71, for a total transaction of $487,083.35. Following the completion of the sale, the director now directly owns 21,751 shares in the company, valued at approximately $2,168,792.21. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider James Hollingshead sold 7,019 shares of the company’s stock in a transaction on Monday, November 20th. The shares were sold at an average price of $84.16, for a total value of $590,719.04. Following the sale, the insider now owns 66,409 shares of the company’s stock, valued at $5,588,981.44. The disclosure for this sale can be found here. Insiders sold a total of 49,802 shares of company stock valued at $4,824,727 over the last 90 days. 1.77% of the stock is currently owned by corporate insiders.
ResMed (NYSE:RMD) traded up $1.79 during trading hours on Friday, hitting $91.05. The company’s stock had a trading volume of 814,244 shares, compared to its average volume of 892,937. The firm has a market cap of $13,233.62, a price-to-earnings ratio of 45.53 and a beta of 0.92. ResMed has a 52-week low of $67.04 and a 52-week high of $104.78.
ResMed (NYSE:RMD) last posted its quarterly earnings results on Monday, January 22nd. The medical equipment provider reported $1.00 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.78 by $0.22. The firm had revenue of $601.27 million for the quarter, compared to analyst estimates of $583.77 million. ResMed had a return on equity of 22.75% and a net margin of 12.98%. The business’s quarterly revenue was up 13.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.73 EPS. sell-side analysts predict that ResMed will post 3.34 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 15th. Investors of record on Thursday, February 8th will be paid a $0.35 dividend. The ex-dividend date is Wednesday, February 7th. This represents a $1.40 annualized dividend and a yield of 1.54%. ResMed’s dividend payout ratio (DPR) is presently 70.00%.
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.